emphasize the more statistically significant end points.
Overall, the reporting of clinical trials appears to bebi- The issues we consideredincluded the analysis of multreatment comparisons should be specified in advance. Bj tiple end points, the analysis of repeated measurements The overuseof arbitrary significance levels (for example, tr overtime, subgroup analyses, trials of multiple treatments, P<0.05) is detrimental to good scientific reporting, and m and the overall number of significance tests in a trial remore emphasis should be given to the magnitudeof treat fie VERthe years there has been a steady improvesuperiority of a treatment are based on evidence rathati ment in the clinical testing of new treatments. er than opinion. As
The randomized, controlled clinical trial has been inHowever,increased sophistication in the conduct of (by creasingly accepted, along with higher standards in clinicaltrials, especially in regard to the use of com various aspects of trial design. We now have more puters for data processing and analysis, has produced precise definitions of patients' eligibility, treatment more available data and more complex statistica Mu schedules, and outcomecriteria; appropriate blinding analysis. For instance,trials often have several meas and objectivity in assessments of patients; and better -_-ures of patient outcome, some of which are assesse? 4 lie data collection and processing. In addition, methods repeatedly during each patient's course of treatment | ful of statistical analysis such as significance testing have subgroups of patients may be analyzed for more spe fg bu become essential features in the reportingoftrial findcific differences between treatments; and more than A OX ings, helping to ensure that any conclusions about the two treatments may be compared, Because of this 2 len large amount of data, there is a danger that sign This paper reviews current practice regarding statistical aspects of clinicaltrial reports by examining a representative sample of recent reports in three medical journals. Methods for assessing the general quality of a trial's conduct and reporting have previously been discussed,'** and several evaluationsoftrials reported in the medical literature have been undertaken.3- § Our aim here is to show how various problemsin the design, conduct, analysis, and reportingofclinical trials lead to potential biases toward presenting findings that can exaggerate the overall perception of progress in clinical research. Wealso discuss guidelines on how to avoid the more commonpitfalls. The reports were published within three months in the Lancet, four months in the British Medical Journal, and six months in the NewEngland Journal of Medicine. The survey included only comparative trials, both randomized (n = 38) and nonrandomized (n = 7). The median number of patients in the trials was 102; nine trials had fewer than 25 patients and two had more than 5000. The trials mvolyed many diseases (including eight infectious, seven cardiovascular, four respiratory, and three digestive disorders) and were considered (o be representativeofcli nicaltrials reported in major medi- Asa reliability check, a random group of 10 trials was reevaluated ( Table | shows the numberof end points mentioned in eachtrial report, as well as the number for which a significant test comparing treatments was performed. The median numberof end points mentioned wassix. Five reports discussed only one end point but three mentioned more than 15, A difference between journals was apparent: the median numbersof end points were three, six, and nine, respectively, in the Lancet, the British Medical Journal, and the New England Journal of Medicine. The differences may have been due to the relative length of reports in the journals.
Significance tests were performed for most. end points. The median numberofsuchtests per trial was four. Three trials used no significance tests for comparing treatments, althoughin one, the response within each treatment group was tested before and after treatment.
For trials with only one end point, the standard interpretation of a significancetest is straightforward: the significance level truly represents the probability of rejecting the null hypothesis of no treatment difference when itis in fact true (the Type I error). Eight trials reported only one end point (one hopes that this was not a post hoc selection from a wider choice of possible end points). However, most trials. reported several end points, thereby increasing the risk of a Type I error. For instance, for a trial with five end points, the chance underthe null hypothesis ofatleast one treatment difference achieving a significance level of P<0.05 is about 20 percent, provided that the end points are not highly correlated. Since many people's interpretations of P values do not take into account Forinstance, one study of extracranial-in tracrania! bypass' identified a primary end point --the occurrence of stroke and stroke-related death in a patientbut also listed three secondary end points. The interpretation of the results is clear and valid. In contrast, a trial studying the suppression of secondary hyperparathyroidism in children® included 12 end points, 1L of which were subjected to significance tests. No priorities were specified, and thetrial included only 12 children. The multiple P values and low statistical power cast doubt on theresults.
On some occasions a single end point cannot be identified in advance. Stricter nominal significance | levels might then be employed by, for instance, using Bonferroni correction methods.9!°This emphasizes the importanceof the size of P values. For example, a trial with 10 or more significance tests and one P value Jess than 0.001 still yields good evidence of a true treatment effect. Alternatively, methods of simultaneous assessment of closely related end points!!!" might be employed.
Subgroup Analyses
In addition to performing an overall comparison of treatmentgroups, it is often relevant to inquire whether treatment differences are more (or less) pronounced in any particular subgroup of patients classified according to prognostic factors. Twenty-three trials in our survey (51 percent) had at least one subgroup analysis that compared the response to treatment in different categories of patients, arid 10 trials included more than one prognostic factor in their subgroup analyses.
A studyofribavirin in the treatment of lassa fever' illustrates the problemis in interpreting subgroupanalyses. Attention is focused on treatment differences based on three prognostic factors (levels of serum aspartate aminotransferase,the extent of viremia, and the time since the onset of fever), with the results presented as P values within the subgroups. Many findings werestatistically significant, but no clear idea wasgiven of the real effects of the prognostic factors on the value of treatment.
The problems here are (1) the overall treatment comparison is not sufficiently prominent, so that the reader gets lost in a morass of subgroup analyses; (2) subgroups were not selected a priori, so that post hoc findings maypresent a selective and distorted picture of the role of prognostic factors; and (3) P values for subgroups are inappropriate for assessing whether the treatment difference varied between subgroups.
Authors can be too eager to explore subgroup analysis in trials containing too few patients for such an evaluation. A more important use of data on prognostic factors is to check that treatment groups are comparable.'® Indeed, 38 trials (84 percent) did report such a base-line comparison of treatment groups. If any noncomparability exists, one can use regression methods to adjust for imbalances in prognostic factors when making an overall comparison of treatments.!" In particular, logistic regression and proportionalhazard models are useful for binary and survival end points, respectively. The importance of a prognostic factor in such regression models may be a useful prerequisite to assessing its possible interaction with treatment. Only nine trials reported such an adjustment for base-line differences. It should be noted that base-line differences should not be detected bysignilicancetesting, since the effect of a prognostic factor on the overall difference in treatment results depends both on its effect on response and the magnitudeofthe imbalance between groups.'®!'
Repeated Measurements over Time
In trials with quantitative measurements of response, such measurements are often made before treatment begins and several times during treatment. Eighteen trials in our survey (40 percent) had such repeated measurements over time. Ten of the trials used descriptive statistics only, but eight reported the results of significance tests at several time points. This repeated testing seriously increases the risk of a Type I error, since authors focus attention on time points with the most significant differences.
For example, one trial'® compared twoactive treat ments for onchocerciasis and a placebo with use of a clinical-reacti on score over six months. Pairwise SI nificance tests were performed daily for 8 days 4" then at 10 days, four weeks, three months, and Si months. This produced 36 P values: the tests were not i ae net ee a Aug. 13, 1987 independe nt, the risk of a 'Type I error waslarge, and interpretat ionis difficult. Two main features appeared to be of interest -the patient's maximal score and the interval during which the score remained above the value obtained with placebo. Appropria te analyses could have been defined a priori -perhaps a test comparing maximal scores and a survival analysis of the times needed to fall below a given score. Other aspects of the data could simply have been displayed graphicall y.
In general, trials with repeated measureme nts need an overall prespecifi ed strategy for statistical analysis.!°Unfo rtunately, this did not appear to have been present in the trials we surveyed. Several possible strategies might be considered , depending on the clinical objectives. First, for each patient, the mean value for observatio ns over a specified time could be taken as the summary measure of response. One is then comparing the average effect of treatments over time. Second, one or two time points for a formal treatment compariso n could be specified in advance. Third, time periods to attain a specified (threshold ) value could be compared. More complex techniques for analyzing repeated measurem ents can be used,?°b ut they are difficult to communic ate to nonstatisticians. A graphic display of the time trends is a valuable supplemen t to any analysis.
Number of Treatment Groups
T'wenty-s ix trials in our survey had two treatmen t groups, and seven others used a two-peri od crossover design. However, nine trials involved three types of treatment s, and threetrial s involved four. The analysis of such multitrea tment trials needs careful consideration. Applyings ignifican cetests to all pairwise differences, as in the trial describe d above, will increase the risk of a Type I error and can make interpret ation difficult, There are methods for compari ng more than two treatmen t groups -e.g., analysis of variance and studentized range methods for quanttat ive data.*! However, many multitrea tment trials compare two active treatment s with either placebo or their combinat ion (or both). A priori hypothes es could then be formulated to compare two groups defined by appropria te amal§amation. Forinstan ce, the Medical Research Council's trial of three treatmen ts for mild hyperten sion (bendrofluazi de, propranol ol, and placebo) " had a primaty hypothesi s compari ng active treatmen t with placebo. A subsidiar y analysis compare d the two active drugs. The specifica tion of such priorities in advance helps to secure a valid interpret ation of multitrea tMent trials, from which the derivatio n of recomme ndations may otherwis e be difficult and controver sial. more extensive use of significan cetests. Table 2 shows the numbero f significa nce tests for treatmen t comparisons reported in the 45 trials we examined . I[t includesall significa nce tests, whether performe d on multiple end points, in subgroup analyses, or on repeated measurem ents over time. The median number of tests per trial was 8; six trials reported more than 20 tests. This may underrepr esent the actual use of significance testing, since authors may select which tests to mention. For instance, some nonsignif icant comparisons may not be explicitly reported as having been tested or may be excluded from the report altogethe r,
The excessive and unstructu red use of significa nce testing in medical articles casts doubt on its credibility, especiall y when people erroneous ly interpret P<0.05 as "proof" of a treatmen t difference . The quality of statistical reporting would be improved if P<0.05 had no special relevance and authors presented actual P values, so that P = 0.04. and P = 0.06 were seen as similar findings of moderate evidence against the null hypothesi s, Trial reports ought to focus on a small number of hypothese s that are specified in advance, so that the principal significa nce tests can be interpret ed without concern about post hoc selection. Subsidiar y analyses (of secondar y end points and patient subgroup s) may still use significa nce tests but in the spirit of cautious and explorato ry data analysis. This is not to deny the value of explorato ry analyses, since any unexpect ed findings should be reported so that they can be confirmed or refuted in subsequen ttrials. Thus, exploratory analyses can be useful for formulati ng new hypotheses, but not for testing them.
Confiden ce Intervals
Because ofthe obsessio n with significa ncetesti ng in the medical literatur e, authors often give insuffici ent attention to estimati ng the magnitu de of treatmen t differenc es. Confide nce intervals express the uncertainty inherent in any trial by presenti ng upper and lower boundsfo r the anticipa ted true treatmen t difference. Several authors have describe d the use of confidenceint ervals for various types of data.?2-3 4 Theyare closely related to significa nce testing: a treatmen t dif. ference thatis significan t at the 5 percent level has a 95 430 percent confidence interval for the difference that is wholly on one side of zero.
Unfortunately, only six trials in our survey (13 percent) made use of confidence intervals. The British Medical Journal now requires more extensive use of confidence intervals (or other estimation methods} -a policy that other journals might wishto follow. For example, the Medical Research Council's trial of treatments for mild hypertension'? reported an observed 45 percent reduction in strokes among patients receiving active treatment as compared with those receiving placebo. Instead of simply quoting P<0.001, the report gave 95 percent confidence limits of 25 and 60 percent for this reduction, a helpful indication of the uncertainty inherent in a comparison of 60 and 109 strokes. A trial of oral magnesium treatmentfor hypertension** reported no statistically significant effect. However, the trial had only 17 patients, and its low powerto detect realistic changes could have been demonstrated by a wide confidence interval.
Intended Size of Trial and Stopping Rules
The intended numberof patients in a clinicaltrial should be determined in advance, and statistical powercalculations are valuable."*°" Only five trial reports in our survey (11 percent) mentioned the intended numberof patients; in each case, this was supported by a statement ofstatistical power. With most trial reports, the reader has no idea whether the investigators (I) had no preset trial size and reported the results at an arbitrary time, with the magnitude (or significance) of the treatment difference possibly af--fecting the decision to'report; (2) failed to achieve the intended trial size and decided to report the trial anyway; (3) extended the trial beyond its intendedsize in order to achieve better statistical power; or (4) reported the trial before the intended trial size was achieved, because interim results showed a substantial treatment difference.
The reader's interpretation oftrial findings depends on which of the four circumstances occurred. For trials with a "negative" conclusion -that is, with no evidence of a treatment difference -possibilities 1 and 2 mayreflect a lack of statistical power and premature publication. Confidence intervals would then be valuable in conveying whetherclinically important differences may exist. For trials with a "positive" conclusion -that is, in which there were some statistically significant treatment effects --possibilities 1, 3, and 4 should instill some caution in the reader. For instance, the authors may have taken repeated looks at the accumulating data and chosen to report the analysis that best highlighted the treatment difference they were hoping to see. In such cases, neither confidence limits nor P values protect sufficiently against the biased timing of publication. These statistical methods allowonlyfor the effects of random variability and cannot correct for injudicious timing or other biases in reporting.
THE NEW ENGLAND JOURNAL OF MEDICINE Aug. 13, 1987 It is ethically desirable to perform interim analyses so that clear evidence of a treatment difference can lead to stopping the trial early. The dangeris that repeated use of significance testing increases therisk of a Type I error. For instance, with 10 interim analy.
ses of one end point, there is a 20 percent chance of reaching P<0.05 even if the null hypothesis is true, This problem becomes moreseriousif thereare sever. al end points or more than two treatments. Severa] statistical stopping rules exist,?""* their essential feature being that allowance for repeated significance testing requires greater treatmentdifferencesin order for a trial to be stopped early.
Only five trials in our survey (11 percent) men. tioned any such stopping rules, and no trial was actually stopped early. Most trial reports mentioned neither an intendedtrial size nor any policy on stopping and publication. This leaves enormous scope for bias in reporting, which in turn affects the credibility of results, since reported P values make no allowancefor the selective timing of publication.
Selection of Results for the Summary
Since the summary or abstract of a clinical trial report receives the greatest attention, it is important that it provide a fair reflection of the trial's findings.
We were concerned about the selection of results for inclusion in the summary. For simplicity, we restricted our evaluation of abstracts or summaries to the 33 reports on trials of two treatments. Each end-point treatment difference in the main text of the article was classified as eitherstatistically significant at the 5 percent level, or not significant at the 3 percent level or not tested. We then noted which end points were mentioned in the summary. Overall, 25 percent of the 130 nonsignificant comparisons were includedin the summary, whereas 70 percent of the 9] significant comparisons were included. Table 3 shows that in seven trials, all reported end points were statistically significant, whereas in another seven, no end points were statistically signif icant. The other 19 trial reports contained a mixture of significant and nonsignificant end points. For these, a stratified Mantel-Haenszel procedure estmates a within-trial relative odds ratio of 9.2:1 for the inclusion of significant:nonsignificant end points in the summary.
This tendency to favor statistically significant re sults when writing atrial summary means that such summaries may exaggerate the true extent of treat ment differences. It is also noteworthy that 15 sum maries (33 percent) provided only the statistical sig" recommendations bear on the whole process ofa clinical trial, from the development of a study protocol to the publication of the report.
(1) Althoughit is valuable for trials to evaluate several aspects of patients' responses, it is important to identify a small set of primary end points in advance. In many trials the design should specify a single primary end point. The results for primary end points (including any nonsignificant findings) should befully reported in both the trial report and its summary or abstract.
(2) Results for secondary end points should be presented as exploratory findings. Any significancetesting of these end points requires cautious interpretation, since there may be many of them and because, by definition, they are not considered priori to be of principal importance.
(3) Subgroup analysis should be confined to a limited numberof prespecified hypotheses concerning the interaction between treatment and a prognostic factor, Statistical tests for interaction should be used, rather than subgroup P values. Subgroupfindings should be interpreted cautiously, in a spirit of exploratory data analysis. If a trial has limited statistical power (i.e., not cnough patients), subgroup analyses should be avoided.
. (4) Trials with repeated measurements of a quantitative end point over time require a prespecified policy for statistical analysis. This should be aimed toward a single specific hypothesis of interest, and repeated significance tests at each time point should be avoided.
(5) For trials with more than two treatments, the primary treatment contrasts should be specified beforehand and emphasized in the report.
(6) Authors should use as few significance tests as possible, so that the risk of a Type I error is imited. Exact P values should be presented, rather than references to arbitrarylevels (e.g., P<0.05). The magnitude of treatment differences for primary end points should be stated, along with the confidence limits,
The intended size of a trial and the mathematical justification of the intendedsize (e.g., powercalculations) should be specified in the Methodssection. Any discrepancy between the actual and intended number of patients should be explained. and intermittent severe periumbilical pain developed, lasted for a day or two, and then becamelocalized in the right lower abdominal quadrant. He cameto the Emergency Ward of this hospital, where moderate anemia was found. An x-ray film of the chest was normal, and an x-ray film of the abdomen showed no abnormality. Oxycodone-acetaminophen wasprescribed, without relief. During the week before -entry the pain was mild and continuous and wasincreased when the patient palpated his abdomen. He observed bright-red blood in bis stools on several occasions. Two days before admission the patient experienced chilliness. On the day of entry nausea developed, and he cameto this hospital. 'The patient wasa police officer. There wasa history of diverticulitis of the colon six years earlier, with similar pain in the right lower abdominal quadrant and hematochezia; the patient was admitted to am other hospital for 10 days and received multiple ant biotics. The diagnosis was reportedly established by a barium-enema examination; the patient was considered in too much pain to endure colonoscop!¢ examination. In the same year he was involved in a motor-vehicle accident that was followed by pet sistent low-back pain, for which he used ibuprofen.
He was said to have hypertension but received N°t reatment for it. There was no history of abdominal 
